Robert T. Abraham
Co-discovered mTOR and showed it directly controls protein synthesis
Mayo Clinic · Duke University Medical Center · Burnham Institute · Pfizer Oncology Research · Vividion Therapeutics · now Engine Biosciences (per most recent record, May 2026)
At Mayo Clinic, isolated mTOR ('RAFT1') using a rapamycin-FKBP12 bait (SAB1995) — one of three independent 1994–95 papers (alongside Schreiber's and Sabatini/Snyder's) founding the field. In 1997 (BRU1997), showed mTOR directly phosphorylates PHAS-I (4E-BP1) — the paper behind nearly every mTOR→translation diagram.
Moved through Duke, Burnham Institute (TOR/ATM-ATR/T-cell signaling), Pfizer Oncology (San Diego), Vividion Therapeutics, now Engine Biosciences — over 30 years still working at the chemical-biology/cancer-drug-discovery interface.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 1995 | M | Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells SAB1995 Isolated mTOR ('RAFT1') via a rapamycin-FKBP12 affinity matrix — one of three independent founding papers. |
| 1997 | M | Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin BRU1997 Showed mTOR directly phosphorylates PHAS-I (4E-BP1), the mechanistic link to protein synthesis control. |